Review Assesses AI Readiness for Deep Brain Stimulation

The authors report that many studies showed encouraging internal performance, but external validation was rare. Evaluations were predominantly retrospective and conducted at single centers. More than one-quarter of the reviewed studies used small-sample, high-dimensional datasets, a combination the authors identify as carrying elevated overfitting risk.

Their technology-readiness assessment places most systems at early-to-intermediate translational stages. The paper attributes this position primarily to limited validation rather than algorithmic inadequacy, alongside biological heterogeneity and the dynamic complexity of DBS.

The review identifies several application areas under investigation:

• •AI-assisted targeting for electrode placement
• •DBS programming
• •Outcome prediction
• •Adaptive therapy delivery

The authors also note emerging external and prospective studies, which they describe as evidence of progress toward clinical maturity.

For ML practitioners working with neurotechnology, the review reinforces a recurring clinical-AI pattern: strong internal metrics do not establish generalizability across sites, patient populations, recording protocols, and treatment workflows. In DBS, model evaluation also has to account for changing neural and behavioral states, rather than treating the clinical setting as a static prediction task.

The findings make prospective and external validation especially consequential for systems intended to influence targeting or stimulation programming. Such applications operate in a safety-critical treatment pathway, where retrospective accuracy alone provides limited evidence about real-world performance. The paper provides a field-level inventory rather than a new model or clinical deployment result, but its synthesis offers a useful benchmark for assessing how close DBS-focused AI research is to routine clinical use.